Established in 2016 Dec., DEARGEN is an IT-BIO start-up developing a drug discovery platform by using artificial intelligence technology. DEARGEN advances the treatment of rare and intractable diseases through the integration of AI and collective intelligence.
The members consist of diverse experts from backgrounds across Deep learning, software, biology and bioinformatics for drug discovery, these brilliant team acts faster than anyone else and consistently moves to face new challenges.
Dr. UG is an AI platform for drug discovery that is based on DEARGEN’s deep learning technology. It specializes in early R&D stage of Drug discovery from Target Discovery to Lead optimization. Dr.UG allows saving time and cost efficiently when compared to traditional methods.
Today, DEARGEN is applying its computational platform to a develop pipeline of drug discovery programs in collaboration with pharmaceutical companies and research institute.
Feb. 2020, Deargen predicted and reported drugs with high potential for treating SARS-CoV-2 using the deep-learning model, MT-DTI. The results include Remdesivir with highest potency, and others such as atazanavir, Kaletra (lopinavir/ritonavir) and hydroxychloroquine, and remdesivir, Kaletra, and hydroxychloroquine are currently on clinical study. The work is formally published on the computational and Structural Biotechnology Journal.
DEARGEN was ranked in TOP Performer in the world at ‘ILSVRC2016’ and ‘NCI-CPTAC DREAM Challenge’ and its technology has been prove.
The AI platform for drug discovery Dr.UG -Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new drugs.
AI-Powered Target Discovery -The ‘DearTRANS’ (Genome Data Analysis) and ‘WX’(Biomarker Prediction) consisting of Dr.UG are DEARGEN's artificial intelligence technologies that specialize in identifying disease-causing targets. Based on each AI technology, genomic data can be quickly compared and analyzed. Also, the disease target's mode of action (MOA) and biomarkers can be predicted.
AI-Powered Drug Design -The DearDTI (Molecule Screening) and MolEQ (Lead Optimization) consisting of Dr.UG are DEARGEN's artificial intelligence technologies that specialize in designing drug candidates for targets. Through the Molecule transformer technology, the affinity score between a target and a small molecule can be predicted. Based on this, small molecule drug candidates with higher efficacy can be designed by ADMET (absorption, distribution, metabolism, excretion, toxicity) optimization
Deargen, predicted a drug with high potential for treatment of a SARS-CoV-2 using the deep-learning technology based AI model MT-DTI. The results is include Remdesivir and chloroquine, and the work is published on the computational and Structural Biotechnology Journal.